Pandemic Influenza
Conditions
Keywords
Prophylaxis, pandemic influenza, influenza A, H5N1 virus
Brief summary
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors as prophylaxis against pandemic influenza infection in patients who are prescribed a long term course in the context of a place of employment or profession. The study is observational only. The primary measure used in this study will be the incidence of symptomatic pandemic influenza in patients receiving prophylaxis. Seroconversion to pandemic influenza, the incidence of adverse events and the relative effectiveness of oseltamivir and zanamivir prophylaxis will also be examined. This project will commence upon pandemic influenza being declared in Australia, Hong Kong or Singapore. Data will be analysed as quickly as possible to help inform the continued use of neuraminidase inhibitor therapy as a cornerstone of the public health agency response to pandemic influenza.
Detailed description
The aim of this study is to 1. Describe the incidence of symptomatic pandemic influenza infection in participants receiving neuraminidase inhibitor prophylaxis in the context of a place of employment or a profession 2. Describe the incidence of seroconversion to pandemic influenza 3. Describe the incidence of adverse events in volunteers taking long term antiviral prophylaxis 4. Compare the effectiveness of oseltamivir and zanamivir prophylaxis The study is an open label prospective cohort study. Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
Interventions
None listed
Sponsors
National Health and Medical Research Council, Australia
Kirby Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Provision of written informed consent * Intention to commence, or already commenced prophylaxis with a neuraminidase inhibitor in the context of a place of employment or profession It is anticipated that participants in this study who are subsequently clinically diagnosed with pandemic influenza will be enrolled in the Index Case protocol (PIPET-A) with follow-up as specified.
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary measure used in this study will be the incidence of symptomatic pandemic influenza in patients receiving prophylaxis. | One month |
Secondary
| Measure | Time frame |
|---|---|
| Seroconversion to pandemic influenza, the incidence of adverse events and the relative effectiveness of oseltamivir and zanamivir prophylaxis will also be examined. | One month |
Countries
Australia
Outcome results
None listed